MSTN and Cachexia: GDF8 has been described as a potent negative regulator of myogenesis in vivo and in vitro and therefore has been a promising therapeutic target in order to promote myogenesis in muscle-wasting conditions, such as age-related atrophy, cachexia, or muscular dystrophies (9).